AICAR has been used clinically to treat and protect against cardiac ischemic injury
Cas No: 2627-69-2
Appearance: white powder
Aicar (AICA-Riboside) strongly inhibits the transcription of PPAR&alpha and the coactivation of PPAR&alpha.
AICAR has been used clinically to treat and protect against cardiac ischemic injury.
In adipocyte studies it has been shown to antagonize lipolysis induced by isoprenaline and has been suggested for use in kinase cascade research. Additionally, research indicates that AICAR blocks the differentiation of 3T3-L1 (sc-2243) adipocytes.
How to use AICAR
In general I would recommend against using AICAR, but if wishing to do so anyway, I would use 500 mg/day for a limited period of time such as 4 weeks. For almost all persons this would be financially impractical with 50 mg pre-prepared vials.
Conforms to structure
Conforms to MW
Complies with enterprise standard